Eli Lilly (LLY)
813.48
+11.83 (1.48%)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues
The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe.

After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers.
Via Chartmill · March 14, 2025

As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via Chartmill · March 14, 2025

CVS Weight Management program members achieved 15% average weight loss, with 92% satisfaction and 26% lower GLP-1 medication costs for participating clients.
Via Benzinga · March 14, 2025

Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.
Via Benzinga · March 14, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 11.2%. This drawdown was much worse than the S&P 500’s 1.1% decline.
Via StockStory · March 14, 2025

Via Benzinga · March 14, 2025

Via The Motley Fool · March 14, 2025

Via The Motley Fool · March 14, 2025

Elanco has gotten torched over the last six months - since September 2024, its stock price has dropped 28.5% to $10.39 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.
Via StockStory · March 14, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQSUPN).
Via StockStory · March 14, 2025

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.
Via Benzinga · March 13, 2025

These 20 blue chip companies are the largest traded on U.S. exchanges.
Via The Motley Fool · March 13, 2025

Ignore the noise in GLP-1 stocks. Find the best value instead.
Via The Motley Fool · March 12, 2025

The company is looking to test a combination of the drug it acquired from Carmot Therapeutics and a amylin-based drug.
Via Investor's Business Daily · March 12, 2025

Shutting down an acquisition caught investor attention, but there's more to the story.
Via The Motley Fool · March 11, 2025

Merck unveils a $1 billion vaccine manufacturing facility in Durham, North Carolina, expanding its U.S. production and research investments.
Via Benzinga · March 11, 2025

These three stocks tumbled by at least 20% last week, but they may not be down for long.
Via The Motley Fool · March 10, 2025

Eli Lilly and Incyte's baricitinib showed significant hair regrowth in adolescents with severe alopecia areata, with results comparable to adults at 52 weeks.
Via Benzinga · March 11, 2025